Science Simplified!

                       JAI VIGNAN

All about Science - to remove misconceptions and encourage scientific temper

Communicating science to the common people

'To make  them see the world differently through the beautiful lense of  science'

Load Previous Comments
  • Dr. Krishna Kumari Challa

    Three scientists win Nobel Prize in chemistry for the development of metal-organic frameworks

    Three scientists won the Nobel Prize in chemistry this week for their development of new molecular structures that can trap vast quantities of gas inside, laying the groundwork to potentially suck greenhouse gases out of the atmosphere or harvest moisture from desert environments.

    Heiner Linke, chairperson of the committee that made the award, compared the structures called metal-organic frameworks to the seemingly bottomless magical handbag carried by Hermione Granger in the "Harry Potter" series. Another example might be Mary Poppins' enchanted carpet bag. These containers look small from the outside but are able to hold surprisingly large quantities within.

    The committee said Susumu Kitagawa, Richard Robson and Omar M. Yaghi were honored for "groundbreaking discoveries" that "may contribute to solving some of humankind's greatest challenges," from pollution to water scarcity.

    The chemists worked separately but added to each other's breakthroughs over decades, beginning with Robson's work in the 1980s.

    The scientists were able to devise stable atomic structures that preserved holes of specific sizes that allowed gas or liquid to flow in and out. The holes can be customized to match the size of specific molecules that scientists or engineers want to hold in place, such as water, carbon dioxide or methane.

    That level of control is quite rare in chemistry.

    A relatively small amount of the structure—which combines metal nodes and organic rods, somewhat like the interchangeable building pieces in Tinker Toys—creates many organized holes and a huge amount of surface area inside.

    Why the work matters

    Today researchers around the world are exploring possibilities that include using the frameworks to remove greenhouse gases from the atmosphere and pollution from industrial sites. Another possibility is to use them to harvest moisture from desert air, perhaps to one day provide clean drinking water in arid environments.

    Scientists are also investigating using the structures for targeted drug delivery. The idea is to load them with medicine that may be slowly released inside the body. It could be a better way to deliver low doses continually.

    The research "could be really, really valuable" in many industries.

    Nobel committee announcement:

    The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2025 to

    Susumu Kitagawa, Kyoto University, Japan

    Richard Robson, University of Melbourne, Australia

    Omar M. Yaghi, University of California, Berkeley, U.S.

    "for the development of metal-organic frameworks"

    Their molecular architecture contains rooms for chemistry

    The Nobel Prize laureates in chemistry 2025 have created molecular constructions with large spaces through which gases and other chemicals can flow. These constructions, metal-organic frameworks, can be used to harvest water from desert air, capture carbon dioxide, store toxic gases or catalyze chemical reactions.

    https://www.nobelprize.org/prizes/chemistry/2025/press-release/

  • Dr. Krishna Kumari Challa

    New type of diabetes discovered in babies

    Advanced DNA sequencing technologies and a new model of stem cell research have enabled an international team to discover a new type of diabetes in babies.

    The researchers established that mutations in the TMEM167A gene are responsible for a rare form of neonatal diabetes.

    Some babies develop diabetes before the age of six months. In over 85% of cases, this is due to a genetic mutation in their DNA. Research  found that in six children with additional neurological disorders such as epilepsy and microcephaly identified alterations in a single gene: TMEM167A.

    To understand its role, the researchers  used stem cells differentiated into pancreatic beta cells and gene-editing techniques (CRISPR). They found that when the TMEM167A gene is altered, insulin-producing cells can no longer fulfill their role. They then activate stress mechanisms that lead to their death.

    This discovery shows that the TMEM167A gene is essential for the proper functioning of insulin-producing beta cells, but also for neurons, whereas it seems dispensable for other cell types. These results contribute to a better understanding of the crucial steps involved in insulin production and could shed light on research into other forms of diabetes, a disease which today affects almost 589 million people worldwide.

    Enrico Virgilio et al, Recessive TMEM167A variants cause neonatal diabetes, microcephaly and epilepsy syndrome, Journal of Clinical Investigation (2025). DOI: 10.1172/jci195756

  • Dr. Krishna Kumari Challa

    Novel blood test for chronic fatigue achieves 96% accuracy

    Scientists  have developed a high accuracy blood test to diagnose chronic fatigue syndrome, also known as myalgic encephalomyelitis (ME/CFS).

    The debilitating long-term illness affects millions worldwide but is poorly understood and has long lacked reliable diagnostic tools.

    With 96% accuracy, the new test offers new hope for those living with the condition—which is often misunderstood and misdiagnosed. It is hoped that the breakthrough could pave the way for a similar blood test to diagnose long COVID.

    Chronic fatigue syndrome is not a genetic disease you're born with. That's why using EpiSwitch 'epigenetic' markers—which can change during a person's life, unlike a fixed genetic code—was key to reaching this high level of accuracy.

    The team discovered a unique pattern that appears consistently in people with ME/CFS that is not seen in healthy people.

    The researchers also found signs of immune system and inflammation pathways involved in the disease, which may help guide future treatments and identify patients more likely to respond to specific therapies.

    'Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling, Journal of Translational Medicine (2025). translational-medicine.biomedc … 6/s12967-025-07203-w